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Vascular E-Selectin Expression Correlates with CD8
Lymphocyte Infiltration and Improved Outcome in
Merkel Cell Carcinoma
Olga K. Afanasiev1,2, Kotaro Nagase3, William Simonson2,4, Natalie Vandeven2, Astrid Blom1,
David M. Koelle4–8, Rachael Clark9 and Paul Nghiem1,2,6
Merkel cell carcinoma (MCC) is an aggressive, polyomavirus-linked skin cancer. Although CD8 lymphocyte
infiltration into the tumor is strongly correlated with improved survival, these cells are absent or sparse in most
MCCs. We investigated whether specific mechanisms of T-cell migration may be commonly disrupted in MCC
tumors with poor CD8 lymphocyte infiltration. Intratumoral vascular E-selectin, critical for T-cell entry into skin,
was downregulated in the majority (52%) of MCCs (n¼ 56), and its loss was associated with poor intratumoral
CD8 lymphocyte infiltration (Po0.05; n¼ 45). Importantly, survival was improved in MCC patients whose tumors
had higher vascular E-selectin expression (Po0.05). Local nitric oxide (NO) production is one mechanism of
E-selectin downregulation and it can be tracked by quantifying nitrotyrosine, a stable biomarker of NO-induced
reactive nitrogen species (RNS). Indeed, increasing levels of nitrotyrosine within MCC tumors were associated
with low E-selectin expression (Po0.05; n¼ 45) and decreased CD8 lymphocyte infiltration (Po0.05, n¼ 45). These
data suggest that one mechanism of immune evasion in MCC may be restriction of T-cell entry into the tumor.
Existing therapeutic agents that modulate E-selectin expression and/or RNS generation may restore T-cell entry
and could potentially synergize with other immune-stimulating therapies.
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INTRODUCTION
Merkel cell carcinoma (MCC) is an increasingly common
neuroendocrine skin cancer that is at least twice as likely to be
lethal as melanoma (Lemos et al., 2010). Although surgery and/
or radiation therapy may be curative for patients with localized
MCC in the absence of distant metastases, relapses are common
and often incurable, with no disease-specific therapies available.
Investigation of mechanisms involved in MCC pathogenesis and
progression could offer rational targets for future therapies.
The cellular immune response against MCC is particularly
relevant in light of the recently discovered causal link between
this cancer and the Merkel cell polyomavirus (MCPyV) (Feng
et al., 2008), as well as the increased MCC incidence among
immune suppressed individuals with HIV, chronic
lymphocytic leukemia, or solid organ transplantation (Penn,
1999; Engels et al., 2002; Heath et al., 2008). Indeed, MCPyV
oncoproteins that are persistently expressed in MCC tumors
have recently been shown to be targets for CD8 and CD4
T cells (Iyer et al., 2011). Furthermore, several studies suggest
that CD8 and CD3 lymphocyte infiltration into MCC tumors is
strongly linked to survival (Paulson et al., 2011; Sihto et al.,
2012). However, this advantageous robust lymphocytic
infiltration into MCC tumors is only present in B20% of
patients (Paulson et al., 2011). Thus, we hypothesized that the
inability of the immune response to control MCC may in part
be because of blockade of lymphocyte entry into MCC tumors.
One mechanism of T-cell exclusion from tumors is down-
regulation of adhesion molecules on tumor vasculature or on
lymphocytes, thereby blocking recruitment of T cells from
blood vessels. In skin, expression of endothelial E-selectin
adhesion molecule is the earliest step of tethering, rolling, and
emigration of cutaneous lymphocyte antigen (CLA)-positive
T cells from blood vessels to sites of inflammation (Kupper
and Fuhlbrigge, 2004) and cancer (Clark et al., 2008). Indeed,
human squamous cell carcinomas have been shown to evade
the immune response by downregulating E-selectin on tumor
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vasculature (Clark et al., 2008). A recent report suggests that
E-selectin expression in squamous cell carcinomas is
downregulated by nitric oxide (NO) produced by tumor-
associated myeloid-derived suppressor cells (Gehad et al.,
2012). Protein nitration is a stable biochemical marker of NO
production and inducible NO synthase/arginase pathway
activation and thus can be tracked in archival tissues using
an antibody against nitrotyrosine. Indeed, several human
cancers, including prostate, colon, and hepatocellular
carcinomas (Kasic et al., 2011), show markedly elevated
levels of nitrotyrosine, which are associated with a lack of
functional tumor-infiltrating lymphocytes (Bronte et al., 2005;
Nagaraj et al., 2007). We therefore investigated the role of
nitrotyrosine and its association with E-selectin
downregulation in, and CD8 lymphocyte exclusion from,
MCC tumors.
In this study, we found that increased numbers of E-selectin-
positive vessels in the tumor are associated with greater
intratumoral CD8 lymphocyte infiltration and improved
MCC-specific survival. The downregulation of E-selectin may
be a consequence of the high levels of nitrotyrosine expression
in MCC tumors. These findings have mechanistic and poten-
tial therapeutic implications for MCC.
RESULTS
The fraction of E-selectin-positive blood vessels is decreased in
the majority of MCC tumors
Vascular E-selectin is critical for the entry of CLA-positive T
cells into the skin under both normal and inflamed conditions
(Kupper and Fuhlbrigge, 2004). To determine the presence of
E-selectin in MCC tumor vasculature, we stained serial
sections of MCC tumors with antibodies to E-selectin and
CD31. A total of 56 MCC tumors from 55 patients were
analyzed. Vascular structures, as identified by staining for
CD31, were apparent both within the tumor and in the
adjacent peritumoral areas (Figure 1). Among the 56 tumors,
the mean number of vessels was similar in intratumoral
(35±19 CD31-positive vessels per 200 magnification field)
and peritumoral areas (44±24). Strikingly however, when
tumors were compared for the fraction of E-selectin-positive
vessels within versus outside the tumor, there was a 4-fold
decrease in the proportion of E-selectin-positive vessels within
the tumor as compared with that in the tumor periphery
(Po0.05; representative tumor seen in Figure 1b). Further
analyses were carried out after stratifying intratumoral or
peritumoral areas into low, moderate, or high bins (o1%,
1–5%, and 45% of vessels being E-selectin-positive,
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Figure 1. Vascular adhesion molecules and CD8 infiltration on representative serial tumor sections. (a; left to right) Serial sections stained as indicated from three
patients (cases w453, w456, and w236) with the specified intratumoral CD8 and E-selectin scores. Red arrowheads indicate areas of positive staining on
immunohistochemistry for the indicated antibody. Bar¼ 100mm. (b; left to right) Serial sections from a Merkel cell carcinoma (MCC) tumor (case w532) with both
stromal and tumor components stained with specified antibodies. Black dashed line indicates the junction between tumor and stroma. The sections shown are
representative of staining patterns in the stroma and tumor. H&E, hematoxylin and eosin. Bar¼ 100mm.
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respectively; Figure 2a). Among 56 MCC tumors, the fraction
of E-selectin-positive vessels inside the tumor was often ‘low’
(52% of MCCs) as compared with the fraction of E-selectin-
positive vessels in peritumoral areas (29% of MCCs; Po0.05).
In contrast, intratumoral areas of MCCs were less likely to
have a high fraction of E-selectin-positive vessels as compared
with peritumoral areas (14% vs. 32%, respectively; Po0.05;
Figure 2a). Next, to investigate if there was a correlation
between E-selectin expression and MCC-specific survival,
we compared the fraction of intratumoral E-selectin-positive
vessels among MCC patients. We observed a significant trend
toward improved survival among patients with tumors expres-
sing a higher fraction of E-selectin-positive vessels within
the tumor vasculature (Po0.05 by log-rank test for trend;
Figure 2b). There were no significant associations between
E-selectin and stage, gender, age, or lesion type.
Intratumoral CD8 infiltration is correlated with
E-selectin-positive vessels
To analyze the relationship of T-cell infiltration with vascular
E-selectin patterns described above, we stained serial sections
of 56 MCC tumor specimens from 55 patients for CD8 and the
indicated vascular markers (Figure 1). Tumor CD8 lymphocyte
infiltration patterns were categorized as previously described
into six bins of density in intratumoral and peritumoral sites
and subsequently into three infiltration patterns (brisk, sparse,
or stalled) (Paulson et al., 2011). Of the 56 tumors, 25% had a
brisk CD8 infiltrate (intratumoral CD8 score of 3–5), whereas
75% had a sparse CD8 infiltrate (intratumoral score of 0–2).
Among 34 tumors with no or very low CD8 intratumoral
infiltrate (intratumoral score of 0 or 1), 41% exhibited a
prominent stalled phenotype with high numbers of peritu-
moral CD8 cells (peritumoral score 3–5) accumulating within
the tissue immediately adjacent to the tumors (representative
example seen in Figure 1b). Among all analyzed tumors, an
increasing fraction of intratumoral E-selectin-positive vessels
was associated with an increasing intratumoral CD8 lympho-
cyte score (Po0.05; Figure 3a). Tumors with a high fraction of
E-selectin-positive vessels had a median CD8 lymphocyte
score of 3.5, with CD8 scores X3 previously reported to be
associated with excellent MCC-specific survival in a large
cohort study (Paulson et al., 2011). In contrast, tumors with a
low fraction of E-selectin-positive vessels had a median CD8
lymphocyte score of zero.
In order to explain the distinct CD8 infiltration patterns in
MCC tumors (brisk, sparse, or stalled as described above), we
compared the relative E-selectin-positive fractions between
intratumoral and peritumoral vessels. Among tumors with
sparse or stalled CD8 infiltrates, the intratumoral E-selectin-
positive fraction was selectively decreased as compared with
the peritumoral E-selectin fraction (Po0.01; Figure 3b). In
contrast, among tumors with robust numbers of CD8 lympho-
cytes in the tumor and surrounding stroma (brisk infiltrate),
E-selectin positivity was preserved among both intratumoral
and peritumoral vessels. Altogether, these studies suggest that
the restriction for CD8 lymphocyte entry into some tumors
may be mechanistically linked to the low E-selectin-positive
proportion of tumor vessels.
Expression of the skin-homing receptor CLA is retained on
MCC-targeting lymphocytes
Because of its key role in facilitating lymphocyte adhesion to
E-selectin and entry into the skin, we determined whether CLA
was expressed on lymphocytes in and around MCC tumors.
MCC tumor sections were costained with CLA and CD8 and
colocalization of these proteins was quantified as a percent of
total CD8 lymphocytes by immunofluorescence analysis
(Figure 4a). Of the 20 tumors, 80% had CLA/CD8 coexpres-
sion that was moderate (n¼ 9, defined as 5–50% CLA-positive
CD8 cells) or high (n¼7; X50% CLA-positive CD8 cells;
Figure 4a). CD8 T cells from blood had similar levels of CLA
expression in MCC patients and control subjects, suggesting
no global dysregulation of CLA expression (Figure 4b). In a
small cohort of MCC patients in which it was possible to
examine MCPyV oncoprotein-specific CD8 T cells from
blood, on average, CLA expression was observed in 39% of
these virus-specific T cells as compared with 7% and 4% on T
cells specific for cytomegalovirus and Epstein–Barr virus,
respectively (Po0.05; Figure 4b). The CLA-negative MCPyV-
specific T cells may represent populations that have been
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Figure 2. Merkel cell carcinoma (MCC) tumors often have decreased E-selectin-positive vessels, which correlate with worse survival. (a) Percent of MCC
tumors with low (o1%), moderate (1–5%), or high (45%) fraction of intratumoral (black bars) or peritumoral (white bars) E-selectin-positive vessels.
*Po0.05, Fisher’s exact test. (b) Kaplan–Meier curves showing MCC-specific survival of patients with low (n¼ 29), moderate (n¼ 18), or high (n¼ 8) fractions of
intratumoral vessels that were E-selectin-positive. P-value determined by log-rank test for trend.
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primed in other nonskin compartments or cells with central
memory rather than effector memory function. Overall, these
data suggest that MCC-targeting CD8 lymphocytes, especially
those in the MCC tumor microenvironment, often express CLA
and would thus be capable of binding its E-selectin ligand
when expressed on blood vessels.
High nitrotyrosine levels are associated with low
E-selectin-positive vessels and poor CD8 lymphocyte infiltration
Recent studies have reported that local production of NO
leads to downregulation of vascular E-selectin and impairment
of T-cell trafficking into tumors (Gehad et al., 2012). Thus, we
stained 236 MCC tumors from 181 patients using an
antinitrotyrosine antibody to evaluate protein nitration
(Molon et al., 2011), which is a consequence of local NO-
mediated production of reactive nitrogen species (RNS)
(Eiserich et al., 1995; Sawa et al., 2000; Radi, 2004; Szabo´
et al., 2007; Nathan and Ding, 2010). Approximately 43% of
MCC tumors (n¼ 101) had moderate or high expression of
nitrotyrosine, with only 6% of tumors completely lacking
nitrotyrosine staining within the tumor microenvironment
(Figure 5a). Furthermore, increasing levels of nitrotyrosine
were associated with lower number of E-selectin-positive
vessels within MCC tumors (Po0.05; Figure 5b). Higher
nitrotyrosine levels were also associated with lower intratu-
moral CD8 lymphocyte scores (Po0.05; n¼45; Figure 5b).
These data suggest that metabolic pathways involving NO and
RNS production may be one of the several mechanisms
regulating T-cell extravasation into MCC tumors.
DISCUSSION
The cellular immune system is particularly important in
controlling MCC given that immune dysfunction is associated
with increased incidence (Penn, 1999; Engels et al., 2002;
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Figure 3. Intratumoral E-selectin is associated with CD8 lymphocytic infiltration into Merkel cell carcinoma (MCC) tumors. (a) Correlation between intratumoral
E-selectin-positive vessels and CD8 lymphocyte infiltration in 56 MCCs. E-selectin was scored as a percent of all vessels and stratified as low (o1%, n¼ 29),
moderate (1–5%, n¼ 19), or high (45%, n¼ 8). CD8 cells were scored on a 0–5 scale (Paulson et al., 2011). Black bar indicates median. *Po0.05, Wilcoxon’s
rank-sum test. (b) Comparison of intratumoral (filled circles) with peritumoral (empty circles) E-selectin-positive vessels among tumors with CD8 infiltrates
characterized as stalled (intratumoral CD8 score p1 and peritumoral CD8 score X3, n¼ 14), sparse (intratumoral CD8 score p2, n¼ 42), or brisk (intratumoral
CD8 score X3, n¼14). Black dots in schematic indicate CD8 lymphocytes. Black bar indicates mean. **Po0.01, Student’s t-test.
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Heath et al., 2008) and diminished survival for MCC (Paulson
et al., 2012). Sparse lymphocyte infiltration observed in the
majority of MCCs suggests that defective T-cell entry may play
a role in the inability to control this highly immunogenic
cancer. Indeed, we report that vascular E-selectin, required
for the recruitment of CLA-positive T cells into the skin, is
downregulated in the majority of MCCs. Tumors with a
higher number of E-selectin-positive vessels are associated
with increased intratumoral CD8 lymphocyte infiltration and
improved MCC-specific survival. Furthermore, we provide
evidence that metabolic pathways leading to production of
nitrotyrosines are associated with E-selectin downregulation
and poor CD8 T-cell infiltration into MCC tumors.
Vascular adhesion molecule expression has clinically
significant implications in a number of human cancers.
Depending on the cancer type, the presence of E-selectin
may be associated with an improved or worsened prognosis.
In breast, colon, and lung cancers, elevated E-selectin expres-
sion on tumor vasculature recruits protumorigenic immune
infiltrates and facilitates attachment and transmigration of
tumor cells through the endothelium, effectively promoting
cancer progression, metastasis, and poorer survival (Mann and
Tanaka, 2011) In contrast, in other cancers, including
squamous cell carcinoma and melanoma, the proportion of
E-selectin-positive vessels is markedly decreased and is
associated with a lack of protective T cells within tumor
nodules (Weishaupt et al., 2007; Clark et al., 2008; Gehad
et al., 2012). The known strong association between
intratumoral lymphocyte infiltration and improved survival of
MCC patients and the predominant absence of protective
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Figure 4. Cutaneous lymphocyte antigen (CLA) expression on Merkel cell carcinoma (MCC)-specific lymphocytes. (a) CLA/CD8 coexpression as evaluated by
immunofluorescence with the indicated stains in a tumor (high CLA/CD8 coexpression; case w588). (a, right) Fraction of MCCs with CLA/CD8 coexpression
categorized as none/low (n¼4,p5% CLA-positive CD8 cells), moderate (n¼ 9, 5–50% CLA-positive CD8 cells), or high (n¼ 7; X50% CLA-positive CD8 cells).
Bar¼50mm. (b) CLA expression in blood as evaluated by flow cytometry. (b, top left) Summary data of CLA expression among CD3þCD8þ cells from control
subjects (subjs; n¼ 10) and MCC patients (pts; n¼8). (b, top right) CLA expression among CD3þCD8þTetramerþ cells specific for MCPyV (n¼ 4),
cytomegalovirus (CMV; n¼ 4), and Epstein–Barr virus (EBV; n¼3). The red dot on each graph indicates the representative sample selected for flow plot display
below. Black bar indicates mean. DAPI, 4,6-diamidino-2-phenylindole; MCPyV, Merkel cell polyomavirus; NS, nonsignificant; Tetþ , tetramer positive. *Po0.05,
Wilcoxon’s rank-sum test.
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lymphocytes in most tumors suggested that vascular
endothelium might play an important role in MCC tumor
immune escape. Thus, we investigated the association
between vascular E-selectin expression, lymphocyte
infiltration patterns and survival in MCC. This study expands
the limited number of reports on E-selectin relevance and its
association with survival in skin cancers. In contrast to other
cancers, where E-selectin is often reported as a biomarker of
metastatic potential and a predictor of worsened outcome, to
our knowledge, the link between intratumoral vascular
E-selectin expression and improved survival has not been
previously reported. The presence of E-selectin in the tumor
vasculature may be particularly important for immunogenic
cancers that are targets of cytotoxic immune cells.
There are several known mechanisms that can contribute to
cellular immune escape and diminished lymphocyte infiltra-
tion. Loss of E-selectin on the tumor vasculature may prevent
adequate leukocyte capture and rolling mediated by E-selec-
tin/CLA interactions on T cells that are capable of reaching the
tumor periphery. Recent evidence suggests that there is a
strong link between vascular E-selectin downregulation and
NO production by myeloid-derived suppressor cells in squa-
mous cell carcinomas (Gehad et al., 2012). It is plausible that
similar mechanisms of E-selectin regulation are at play in
MCC. Indeed, we observed that nitrotyrosine, a surrogate
marker of NO and RNS production, is associated with
E-selectin downregulation and deficient CD8 lymphocyte
infiltration. Beyond E-selectin downregulation, additional
nitrotyrosine-mediated mechanisms of T-cell immune
evasion include: (1) block of signaling and responsiveness to
antigen via TCR/CD3z nitration (Nagaraj et al., 2010), (2)
block of TCR/HLA interactions and tumor recognition by TCR/
CD8 nitration (Nagaraj et al., 2007), and (3) prevention of
T-cell migration via nitration of chemokines that renders them
dysfunctional (Molon et al., 2011).
Suboptimal clinical outcomes of adoptive T-cell therapy for
immunogenic cancers may be in part due to lack of T-cell
recruitment into tumors. Downregulation of vascular E-selec-
tin and tumor protein nitration present obstacles for appro-
priate tumor entry and activity of therapeutic tumor-targeting
T cells. Importantly, studies in a variety of cancers suggest that
improved T-cell infiltration and function may be achieved by
therapeutic modulation of pathways regulating E-selectin
(Clark et al., 2008) and protein nitration (Molon et al.,
2011). Specifically, E-selectin induction has been observed
in vitro with tumor necrosis factor-a and IL-1 cytokines (Wyble
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Figure 5. High levels of tissue nitrotyrosine are associated with a reduced fraction of E-selectin-positive vessels and poor CD8 lymphocyte infiltration.
(a) Representative Merkel cell carcinoma (MCC) tumor cores stained for nitrotyrosine (brown). Nitrotyrosine scores took into account both intensity and proportion
and were categorized as none (n¼14), low (n¼ 121), moderate (n¼80), and high (n¼ 21) expression. Bar¼ 50mm. (b) Correlation between nitrotyrosine
levels and intratumoral E-selectin (left) and CD8 (right) scores among 45 MCC tumors. Black bar represents median. P-value determined by Cuzick’s nonparametric
test for trend.
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et al., 1997), angiostatins (Luo et al., 1998), and topical
imiquimod (Clark et al., 2008). Recent studies also showed
that inhibitors of NO synthase activity were effective in both
E-selectin upregulation (Gehad et al., 2012) and reversal of
nitrotyrosine-associated T-cell dysfunction (Bronte et al.,
2005; De Santo et al., 2005). Furthermore, drugs that block
the generation of RNS can increase tumor-specific CD8
T-cell recruitment and reduce tumor growth when given in
combination with adoptive immunotherapy in mice (Molon
et al., 2011).
This study was limited to the examination of formalin-fixed,
paraffin-embedded human MCC tissues. Future investigations
on fresh or frozen MCC tumors using multicolor immuno-
fluorescence markers may reveal the phenotypic identity of
cells that induce protein nitration of MCC tumors. All of our
studies were on human tissue, and hence reflected human
disease, but this posed obstacles in determining causality of
our observations. Although an animal model would have
advantages, existing MCC xenograft models require pro-
foundly immune deficient mice, and thus would not be able
to address most of the relevant aspects of the immune
response in MCC. It is plausible that future studies in
transgenic mouse models that mimic MCC pathogenesis (such
as the spontaneous carcinogenesis model induced by sporadic
SV40 polyomavirus oncoprotein expression; (Cze´h et al.,
2010)) may be useful in studying immune responses to
molecules that target E-selectin, nitrotyrosine, and
elucidating other relevant mechanisms involved in T-cell
trafficking such as NF-kB regulation of adhesion molecules
and chemokines (Liou, 2002). Furthermore, trials in MCC
patients using E-selectin upregulating agents as discussed
above may validate the observed associations between
E-selectin upregulation, enhanced CD8 lymphocyte
infiltration, and improved survival. Although we have
limited our studies of cutaneous immunosurveillance to
investigation of E-selectin, other contributory mechanisms
include the recruitment of CCR8þ T cells by constitutively
expressed CCL1 in the skin (Schaerli et al., 2004) and platelet
(P)-selectin mediated cutaneous T-cell migration (Kulidjian
et al., 2002).
In summary, this study provides insight into immune
evasion mechanisms that likely play a role in diminishing
lymphocyte entry into MCC tumors. As it is feasible to target
these pathways using existing or emerging agents, it may be
appropriate to combine such treatment with adoptive T-cell
therapy to improve migration of T cells into tumors and
thereby augment the efficacy of future immune therapy.
MATERIALS AND METHODS
Tissue and blood samples
This study was approved by the Fred Hutchinson Cancer Research
Center Institutional Review Board and conducted according to the
Declaration of Helsinki Principles. Written informed consent was
received from participants before inclusion in the study. A total of 248
formalin-fixed, paraffin-embedded tumors from 192 patients were
analyzed (Table 1). Blood samples were collected from MCC patients
(n¼ 11) and healthy volunteers (n¼ 10) who were used as control
subjects.
Immunohistochemistry and immunofluorescence
Serial tumor sections were stained with hematoxylin and eosin, and
with antibodies against E-selectin (clone 16G4, 1:50 dilution; Novo-
castra, Buffalo Grove, IL), CD31 (clone JC70A, 1:100 dilution; Dako,
Carpinteria, CA), CD8 (clone 4B11, 1:200 dilution; Novocastra), CLA
(clone HECA-452, 1:100 dilution; BioLegend, San Diego, CA), and
nitrotyrosine (rabbit polyclonal, 1:250 dilution; Millipore, Billerica,
MA). The specificity of the nitrotyrosine antibody was validated using
colon tissue treated with peroxynitrite as a positive control and
degraded peroxynitrite as a negative control (Supplementary Figure
S1 online) (Sawa et al., 2000; Molon et al., 2011). Scoring for all
studies was performed by observers who were blinded to all subject
characteristics.
Intratumoral and peritumoral E-selectin-positive vessels were
scored among 56 MCC tumor specimens from 55 patients using a
three-tiered system: absent/low¼o1%, moderate¼ 1–5%, and high
45%, expressed as a percent of CD31-positive vessels in serial
sections. The score represented the average fraction of E-selectin-
positive vessels in the entire intratumoral or peritumoral areas with at
Table 1. Patient demographics
Number (%)
MCC patient and tumor characteristics Subjects Tumors Blood
Total number in all studies 196 248 11
E-selectin studies 55 56 —
CD8 studies 55 56 —
CLA studies 31 20 11
Nitrotyrosine studies 181 236 —
Sex
Male 129 (66%)
Female 67 (34%)
Age
o65 60 (31%)
X65 136 (69%)
MCC stage at presentation
I (Local p2 cm) 45 (23%)
II (Local 42 cm) 29 (15%)
III (Nodal) 73 (37%)
IV (Distant metastasis) 20 (10%)
Unknown 29 (15%)
Lesion type studied (n¼ 248)
Primary 154 (62%)
Regional metastasis/recurrence 58 (23%)
Distant metastasis 22 (9%)
Unknown 14 (6%)
Abbreviations: CLA, cutaneous lymphocyte antigen; MCC, Merkel cell
carcinoma.
Patients with nodal presentation and unknown primary are represented in
the ‘‘regional metastasis’’ lesion type. Because of insufficient data, 29
patients could not be staged and are listed as ‘‘unknown.’’ A total of 248
tumors were analyzed from 192 patients in at least one of the studies. Four
additional patients donated blood only for the CLA study.
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least 8–10 tumor fields scored when possible. To compare peritu-
moral and intratumoral areas, the fold difference (ratio of the
percentages of E-selectin-positive vessels) was calculated for each
tumor, and then averaged over all tumors. Intraobserver variability
was evaluated in a random sample of 13 tumors. Observed agree-
ment was 80% and weighted k-statistic was 0.55, consistent with fair
to good agreement between observers (Fleiss, 1981).
Fifty-six MCC tumors from 55 patients were assessed for CD8
lymphocytes using a previously described scoring system (Paulson
et al., 2011). Briefly, intratumoral and peritumoral CD8 infiltrates
were scored separately on a 0–5 scale with 0 representing no CD8
cells and 5 representing a strong CD8 infiltrate. Approximate numbers
of CD8þ cells per mm2 were quantified for each 0–5 bin (with an
average of 0, 90, 306, 508, 675, 732þ CD8 cells per mm2,
respectively). Intratumoral CD8 lymphocytes were those that were
surrounded by tumor cells and did not have direct contact with
stroma. Tumor CD8 lymphocyte infiltration patterns were categorized
as sparse (intratumoral CD8 scorep2), brisk (intratumoral CD8 score
X3), or stalled (intratumoral CD8 score p1 and peritumoral CD8
score X3).
For dual staining of CLA and CD8 immunofluorescence studies,
sections were incubated with anti-CLA as above followed by
biotinylated goat-anti-rat (1:50; Jackson ImmunoResearch, West
Grove, PA) and streptavidin AlexaFluor-568 (1:200; Invitrogen, Grand
Island, NY). The same sections were stained with anti-CD8 (1:50,
clone C8/144B; Dako) followed by goat-anti-mouse AlexaFluor-647
(1:50; Invitrogen). 4,6-diamidino-2-phenylindole was used for nuclear
staining. CLA/CD8 coexpression was quantified as the number of
cells with CLA and CD8 colocalization as a percent of total CD8-
positive cells. The fraction of CD8 lymphocytes coexpressing CLA
was assessed in the whole tissue specimen and was categorized as
none/low (o5%), moderate (5–50%), or high (X50%). Sections were
captured using ScanScope model FL (Aperio, Vista, CA), acquired and
analyzed with Spectrum version 11.1.1.764 (Aperio), and confirmed
with Definiens Architect XD Tissue Studio IF software version 2
(Definiens, Carlsbad, CA).
Three observers assessed nitrotyrosine staining. Tissue microarrays
of tumor cores were scored using a semiquantitative integrated assess-
ment of intensity and proportion staining and categorized as follows:
none, low, moderate, or high staining. The median of the observers’
scores was calculated. Tissue microarray cores contain mostly tumor
cells, but both tumor and stroma areas were included in the score.
Flow cytometry analysis
Peripheral blood mononuclear cells were thawed from cryopreserved
heparinized blood separated with Ficoll/Hypaque. Lymphocytes were
incubated with allophycocyanin-conjugated HLA/peptide tetramers
specific for MCPyV (A24/MCPyV.LT-92-101), cytomegalovirus (A2/
CMV.pp65.495-503), or Epstein–Barr virus (A2/EBV.BMLF1.280-288)
for 30 minutes at 37 1C. Fc receptor blocking reagent (Miltenyi Biotec,
Auburn, CA) was then added for 10 minutes at 4 1C. Next, cells were
stained with CD3-Qdot605 (clone 7D6/S4.1; Invitrogen), CD8-V500
(clone RPA-T8; BD Biosciences, San Jose, CA), and CLA-FITC (clone
HECA-452; BioLegend) for 30 minutes at 4 1C. Cells were washed and
fixed. Events were collected on a FACSAriaII machine (BD Biosciences)
and analyzed using FlowJo software (Tree Star, Ashland, OR). Analysis
and gating were carried out on CD3þCD8þ or CD3þCD8þ
Tetramerþ T cells from the blood of MCC patients or control subjects.
Statistical analysis
Wilcoxon rank-sum test was used to assess significance among
categorically ordered groups. Cuzick’s nonparametric test for trend
(Cuzick, 1985) was used to assess trend across ordered groups.
Student’s t-test was performed when comparing means among two
groups. Fisher’s exact test was used to determine associations
between two categorical variables. Kaplan–Meier survival curves of
cause-specific survival were generated using preselected E-selectin
category cutoffs (low, moderate, high) and statistical significance was
determined using log-rank test for trend. The P-value of o0.05 was
considered significant. All analyses were performed with Stata soft-
ware (StataCorp, College Station, TX).
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